Organizations Filed Purposes:
THE MISSION OF PATH DRUG SOLUTIONS (PDS) IS TO DEVELOP AND ADVANCE SAFE AND EFFECTIVE MEDICINES FOR THE PREVENTION AND TREATMENT OF DISEASES DISPROPORTIONATELY AFFECTING WOMEN AND CHILDREN IN LOW-RESOURCE SETTINGS. WE WORK WITH A VARIETY OF PUBLIC- AND PRIVATE-SECTOR STAKEHOLDERS TO BUILD CROSS-SECTOR COLLABORATIONS, SECURE INTELLECTUAL PROPERTY, REVISIT PROMISING DRUGS OR DRUG CANDIDATES THAT HAVE BEEN SET ASIDE FOR NONMEDICAL REASONS (E.G., LACK OF EARNING POTENTIAL), AND HARNESS SCIENTIFIC AND MANUFACTURING CAPACITY IN COUNTRIES AROUND THE WORLD TO ENSURE THAT DRUGS ARE AVAILABLE, ACCESSIBLE, AFFORDABLE, AND ACCEPTABLE AND THAT SUPPLIES ARE SUSTAINABLE TO ALL THOSE WHO NEED THEM.
SEE PART III, LINE 1.
IN NOVEMBER 2017, THE PDS BOARD DISCUSSED DISSOLUTION PDS. IN 2018, A NUMBER OF ACTIVITIES WERE CARRIED OUT TO COMPLETE THE DISSOLUTION PROCESS, INCLUDING PRODUCT PATENT TRANSFERS FROM PDS TO PATH, ENGAGEMENT OF LEGAL COUNSEL FOR DISSOLUTION PROCEDURES, AND OTHER ADMINISTRATIVE WORK. ON DECEMBER 31, 2018, THE DISSOLUTION OF PDS WAS FORMALLY RECOGNIZED BY THE CALIFORNIA SECRETARY OF STATE.IN JANUARY 2018, FOLLOWING THE CONCLUSION OF THE PHASE 2 CLINICAL STUDY OF RILPIVIRINE LA, A LONG-ACTING INJECTABLE DRUG TO PREVENT INFECTION WITH HIV WHEN USED BEFORE EXPOSURE, PDS COMPLETED ALL REMAINING STUDY CLOSE-OUT ACTIVITIES. THE INVESTIGATIONAL NEW DRUG APPLICATION FOR RILPIVIRINE LA HAS BEEN PLACED IN AN INACTIVE STATUS WITH THE US FOOD AND DRUG ADMINISTRATION, AND THE PROJECT IS NOW FINISHED.IN 2018, PDS CONTINUED WORK TO REDUCE THE BURDEN OF VISCERAL LEISHMANIASIS, ALSO KNOWN AS KALA-AZAR. KALA-AZAR IS A PARASITIC DISEASE COMMON IN AFRICA AND ASIA AND IS ALMOST ALWAYS FATAL IF LEFT UNTREATED. PDS SUPPORTED THE GOVERNMENT OF NEPAL IN ACTIVE CASE DETECTION USING BOTH A CAMP-BASED APPROACH AND AN INDEX CASE-BASED APPROACH IN KALA-AZAR ENDEMIC DISTRICTS. PDS ALSO HOSTED AN INTERNATIONAL POST-KALA-AZAR DERMAL LEISHMANIASIS (PKDL) CONSORTIUM MEETING TO PROVIDE GUIDANCE ON IMPROVING DIAGNOSIS, TREATMENT, AND FOLLOW-UP OF PKDL CASES.TO BUILD CLINICAL RESEARCH CAPACITY IN INDIA, PDS WORKED TO FURTHER DEVELOP AND IMPLEMENT A CLINICAL RESEARCH TRAINING AND MENTORSHIP PROGRAM. THIS WORK WAS DONE IN COLLABORATION WITH THREE NATIONAL CLINICAL RESEARCH RESOURCE CENTERS SPECIALIZING IN PHARMACOVIGILANCE, RESEARCH ETHICS, AND DATA MANAGEMENT.
Executives Listed on Filing
Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing
| Name | Title | Hours Per Week | Total Salary |
|---|
| Dan Hartman | DIRECTOR | 2 | $0 |
| Ken Duncan | DIRECTOR | 2 | $0 |
| Keith Chirgwin | DIRECTOR | 2 | $0 |
| Jorge Flores | DIRECTOR | 1 | $0 |
| David C Kaslow | DIRECTOR | 1 | $0 |
| Daniel Laster | SECRETARY | 1 | $0 |
| Olivia D Polius | TREASURER & CFO | 1 | $0 |
| Stephen B Davis | BOARD CHAIR & PRESIDENT | 1 | $0 |
Data for this page was sourced from XML published by IRS (
public 990 form dataset) from:
https://s3.amazonaws.com/irs-form-990/201923169349306087_public.xml